Hematology · 4 h ago
Cryptic inherited marrow failure was uncommon after negative pediatric SAA workup
A retrospective study used enhanced whole-exome sequencing to assess inherited bone marrow failure syndromes in 153 children with severe aplastic anemia. Among 113 patients without clinical or laboratory features suggesting an inherited syndrome, none had a diagnostic pathogenic or likely pathogenic variant.
- No diagnostic IBMFS variants among 113 patients with negative clinical workup.
- One suggestive case had unresolved ERCC6L2 variant phasing.
- Authors highlight potential risks of delaying SAA treatment.
Distinguishing inherited bone marrow failure syndromes (IBMFS) from acquired severe aplastic anemia (SAA) can affect treatment and long-term management. In this retrospective study, researchers performed enhanced whole-exome sequencing focused on IBMFS-associated genes in 153 pediatric patients with SAA; comprehensive clinical and laboratory data were available for 149.
Among 113 patients (75.8%) with no clinical or laboratory features of IBMFS, sequencing identified no pathogenic or likely pathogenic variants diagnostic of an inherited syndrome. Of the 36 patients with at least one suggestive finding, one had a pathogenic SAMD9L variant and a consistent clinical history. Another had two pathogenic ERCC6L2 variants, but their allelic phasing—and therefore the patient’s affected status—could not be determined.
The authors conclude that cryptic IBMFS was uncommon when comprehensive standard clinical and laboratory evaluation was negative. They note that the potential benefit of waiting for genetic results in such patients should be weighed against risks from delaying SAA treatment. The findings are retrospective and do not establish that genetic testing can be omitted; the study also reports limited numbers of potentially affected patients.
In practice
For children with severe aplastic anemia whose comprehensive clinical and laboratory evaluation shows no features of an inherited bone marrow failure syndrome, this cohort found no diagnostic pathogenic or likely pathogenic variants among 113 such patients tested. The result suggests a low observed yield of sequencing in this subgroup, but does not establish that testing can safely be omitted or define the safest treatment timeline. The retrospective findings support weighing the possible value of awaiting results against risks of treatment delay; they do not prescribe a specific approach.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Blood: Low Incidence of Cryptic Genetic Marrow Failure in Pediatric Severe Aplastic Anemia Following Negative Clinical Workup ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.